摘要 ： 2025年质谱领域发布了哪些具有突破性的新品？面向未来，质谱应该以什么样的形态，更高 效地服务于科研、临床与产业？ 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 2026年伊始，回望过去的一年，对年度新品的系统梳理成为观察行业技术走向的一个重要窗 口。那么，在2025年，质谱领域发布了哪些具有代表性的新品？这些新品背后又折射出怎样 的技术演进逻辑与市场判断？ 本文将对2025年质谱仪新品进行梳理盘点，并结合技术革新路径、应用场景与市场变化，对 行业技术演进方向进行分析。 | | | 2025年进口质谱新品速览 | | | | --- | --- | --- | --- | --- | | | | (以下排序不分先后) | | | | 序号 | 公司名称 | 仪器名称 | 类型 | 上市时间 | | 1 | 珀金埃尔默企业管理 | QSight 500三重四极杆液质 | 三重四极杆 | 2025年3月 | | | (上海)有限公司 | 联用仪 | | | | | 赛默飞色谱与质谱 | Thermo Scientific 1 Or ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future investment returns [5]. Core Viewpoints - The company experienced revenue pressure in Q2 2025, with a year-on-year revenue decrease of 6.65% to 2.06 billion yuan, while net profit decreased by 7.83% to 571 million yuan. However, the second quarter showed a slight improvement in net profit, which increased by 1.97% to 301 million yuan [1][2]. - The company is focusing on innovation through increased R&D investment, which reached 350 million yuan in the first half of 2025, accounting for 16.99% of revenue. The introduction of new products is expected to drive revenue growth [2][3]. - The company has upgraded its AI-assisted clinical decision-making system, enhancing disease risk assessment capabilities and integrating with laboratory information systems for improved service delivery [3]. Summary by Sections Financial Performance - In H1 2025, the company reported a revenue of 2.06 billion yuan, down 6.65% year-on-year, and a net profit of 571 million yuan, down 7.83%. In Q2 2025, revenue was 1.06 billion yuan, a decrease of 4.79%, while net profit increased by 1.97% to 301 million yuan [1][2]. - The company’s R&D expenses decreased by 34.22% to 120 million yuan, contributing to profit improvement through cost reduction [2]. Product Development - The company has launched several innovative products, including the AutomsTQ6000 liquid chromatography-tandem mass spectrometry system and the Autof T series of microbial mass spectrometry detection systems. These new products are expected to enhance revenue growth [2]. Profit Forecast and Valuation - The profit forecast for 2025-2027 is maintained at 1.26 billion yuan, 1.47 billion yuan, and 1.72 billion yuan respectively, with corresponding P/E ratios of 19, 16, and 14 times [3][4].